EML4 and non-small cell lung carcinoma: Of greatest interest is the observation that patients with an EML4-ALK variant 1 (E13:A20) exhibit better outcomes with crizotinib treatment than patients without this variant49, suggesting that ALK variants might influence the response duration of crizotinib in ALK-positive NSCLC.